Beyond this, even if real-world studies confirm the effectiveness of the APT regimen in stage I HER2 + BC, one question remains open: is weekly paclitaxel chemotherapy and one year of trastuzumab truly necessary for all patients? Here, ERBB2 is linked to breast cancer.